A Phase 1/2 interventional study of CB-103 in Breast Cancer, Colorectal Cancer and Adenoid Cystic Carcinoma, sponsored by Cellestia Biotech AG. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Cellestia Biotech AG · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 286 under way, 84 of them phase 3. Breast Neoplasms · Spain.
Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 552nd largest by enrollment of the 805 interventional ones that give a count, is one of 40 that started in 2017, is one of 70 in phase 1/2, and was the 456th registered.
14,829 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Sites in Spain
Ages 18+
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in Spain, United States, Belgium and 5 more countries
Ages 18+
Kenko Imalytics S.L. · Sites in Spain
Ages 18+ · Women only
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
905 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 326 · Phase 3 224 · Phase 4 13
First in 1996; this study’s year is marked. 40 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is close to the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 151 across the 805 interventional studies, 200 across the 97 observational. Of the 575 that completed or were terminated, 291 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
533 of 905 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Cellestia Biotech AG as lead sponsor.
Cellestia Biotech AG has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
80 of the studies in Breast Neoplasms with a site in Spain that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
Add all 80 to your calendar (.ics) → With an account.
Among the 905 studies in Breast Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages: dose escalation in Part A of the study (Phase I) followed by dose expansion in Part B (Phase IIA).
Escalation cohorts will receive repeat doses of CB-103 to determine the MTD and RP2D.
CB-103 will be administered orally in treatment cycles of 28-days each. Aim of the expansion Phase IIA, Part B of the study will be to collect preliminary evidence of anti-tumour activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease
EXCLUSION CRITERIA
Medical History
History of second or other primary cancer with the exception of:
Prior Therapy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CB-103 capsules will be administered orally in treatment cycles of 28-days each.
Drug: CB-103
Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
Dose Limiting Toxicity (DLT)
Number of patients with dose limiting toxicity during the first cycle. DLT is defined as a severe adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications, that occurs ≤ 28 days following the first dose of CB-103 (Cycle 1).
Time frame: 28 days
Overall Response Rate
Number of patients with an overall response rate (CR+PR assessed by RECSIT v1.1 or CR or CRi by NCCN guidelines) up to 24 months
Time frame: 24 months
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 3 | 7 | 7 | 3 | 4 | 3 | 9 | 5 | 6 | 4 | 8 | 15 |
| Completed | 5 | 3 | 7 | 7 | 3 | 4 | 3 | 9 | 5 | 6 | 4 | 8 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of patients with dose limiting toxicity during the first cycle. DLT is defined as a severe adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications, that occurs ≤ 28 days following the first dose of CB-103 (Cycle 1).
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
Number of patients with an overall response rate (CR+PR assessed by RECSIT v1.1 or CR or CRi by NCCN guidelines) up to 24 months
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate | 1 | 2 | 5 | 5 | 2 | 1 | 2 | 4 | 2 | 5 | 1 | 4 | 3 |
Collected over From Cycle 1 Day 1 through Safety Follow-up (28 days after the last dose of CB-103), up to 24 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort 2 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Cohort 3 | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Cohort 4 | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Cohort 5 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Cohort 6 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Cohort 7 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 8 | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Cohort 9 | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Cohort 10 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Cohort 11 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Cohort 12 | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Confirmatory Cohort | 0/15 (0%) | 1/15 (6.7%) | 9/15 (60%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Steven-Johnson SyndromeSkin and subcutaneous tissue disorders | 0/5 | 0/3 | 0/7 | 0/7 | 0/3 | 0/4 | 0/3 | 0/9 | 1/5 | 0/6 | 0/4 | 0/8 | 0/15 |
| Drug Induced Liver InjuryHepatobiliary disorders | 0/5 | 0/3 | 0/7 | 1/7 | 0/3 | 0/4 | 0/3 | 0/9 | 0/5 | 0/6 | 0/4 | 0/8 | 0/15 |
| Liver Function Test IncreasedHepatobiliary disorders | 0/5 | 0/3 | 0/7 | 0/7 | 0/3 | 0/4 | 0/3 | 0/9 | 0/5 | 0/6 | 0/4 | 0/8 | 1/15 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| dyschromatopsiaEye disorders | 0/5 | 0/3 | 0/7 | 0/7 | 0/3 | 0/4 | 0/3 | 2/9 | 1/5 | 5/6 | 3/4 | 3/8 | 1/15 |
| anaemiaBlood and lymphatic system disorders | 0/5 | 0/3 | 0/7 | 0/7 | 0/3 | 0/4 | 1/3 | 1/9 | 2/5 | 2/6 | 2/4 | 3/8 | 2/15 |
| fatigueGeneral disorders | 1/5 | 1/3 | 1/7 | 0/7 | 0/3 | 0/4 | 1/3 | 1/9 | 1/5 | 1/6 | 2/4 | 0/8 | 0/15 |
| diarrhoeaGastrointestinal disorders | 1/5 | 0/3 | 3/7 | 1/7 | 0/3 | 1/4 | 0/3 | 2/9 | 0/5 | 1/6 | 0/4 | 1/8 | 0/15 |
| NauseaGastrointestinal disorders | 2/5 | 1/3 | 2/7 | 2/7 | 0/3 | 0/4 | 1/3 | 2/9 | 1/5 | 2/6 | 0/4 | 1/8 | 3/15 |
| vision blurredEye disorders | 0/5 | 0/3 | 0/7 | 1/7 | 1/3 | 1/4 | 0/3 | 2/9 | 1/5 | 2/6 | 0/4 | 3/8 | 1/15 |
| dyspepsiaGastrointestinal disorders | 0/5 | 0/3 | 1/7 | 0/7 | 0/3 | 1/4 | 0/3 | 3/9 | 0/5 | 2/6 | 0/4 | 1/8 | 2/15 |
| vomitingGastrointestinal disorders | 0/5 | 0/3 | 0/7 | 0/7 | 1/3 | 0/4 | 0/3 | 2/9 | 1/5 | 2/6 | 1/4 | 2/8 | 2/15 |
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 4 | 5 | 3 | 3 | 2 | 5 | 3 | 5 | 3 | 4 | 12 | 55 |
| >=65 years | 2 | 0 | 3 | 2 | 0 | 1 | 1 | 4 | 2 | 1 | 1 | 4 | 3 | 24 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 57.2 (39 to 74) | 55.7 (39 to 74) | 52.7 (25 to 67) | 54.4 (38 to 70) | 51.3 (44 to 62) | 54.8 (41 to 69) | 61.7 (49 to 76) | 56.6 (28 to 76) | 64.6 (56 to 75) | 54 (42 to 72) | 51.5 (23 to 74) | 58.6 (25 to 75) | 46.9 (23 to 71) | 54.4 (23 to 76) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 3 | 3 | 3 | 2 | 2 | 5 | 2 | 4 | 1 | 2 | 5 | 34 |
| Male | 4 | 2 | 4 | 4 | 0 | 2 | 1 | 4 | 3 | 2 | 3 | 6 | 10 | 45 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| White | 5 | 3 | 7 | 7 | 2 | 4 | 3 | 9 | 4 | 6 | 4 | 7 | 9 | 70 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8 | Cohort 9 | Cohort 10 | Cohort 11 | Cohort 12 | Confirmatory Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| South Korea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 |
| United States | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 5 | 3 | 13 |
| Switzerland | 1 | 2 | 3 | 3 | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 15 |
| Germany | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 5 |
| Spain | 4 | 1 | 4 | 4 | 3 | 4 | 2 | 5 | 3 | 3 | 0 | 2 | 2 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Nov 2022, 59 months.
Results were first posted in Jan 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Limantrafin